Date: | ||
Time: | ||
Format: | Panel Discussion - Executing a Successful Product Launch During a Pandemic | |
Attendees: | Carrie Bourdow, President & CEO | |
Webcast: | https://wsw.com/webcast/lifesci/panel14/2387307 | |
Date: | ||
Time: | ||
Format: | Fireside Chat | |
Attendees: | Carrie Bourdow, President & CEO | |
Webcast: | https://journey.ct.events/view/940f6f19-b43a-471d-8bab-6aa4e8e612e0 |
Links to the webcasts will be available on the Events page of the Investors section on the Company’s website at www.trevena.com/investors/events-presentations/ir-calendar.
About Trevena
For more information, please visit www.Trevena.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “objective,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “ongoing,” or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company’s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the
For more information, please contact:
Investor Contact:
Managing Director
daniel@lifesciadvisors.com
(617) 430-7576
Company Contact:
SVP and Chief Commercial Officer
(610) 354-8840
Source:
2021 GlobeNewswire, Inc., source